Skip to main content
. Author manuscript; available in PMC: 2016 May 23.
Published in final edited form as: Clin Adv Hematol Oncol. 2014 May;12(5):332–334.

Figure.

Figure

In an analysis of data from the phase 3 IMPACT trial of sipuleucel-T, improved overall survival was seen in patients who showed an immunoglobulin G response to the primary antigen and any 3 secondary antigens.

IMPACT, Immunotherapy Prostate Adenocarcinoma Treatment.

Adapted from Drake CG et al. ASCO GU abstract 88. J Clin Oncol. 2014;32(4)(suppl).